Compile Data Set for Download or QSAR
Report error Found 597 with Last Name = 'yule' and Initial = 'i'
TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310923({6-Methylamino-2-[(pyridin-3-ylmethyl)-amino]-thie...)
Affinity DataIC50: 1.40nMAssay Description:The use of a Fluorometric Imaging Plate Reader (FLIPR) to measure calcium flux in Adenosine-receptor expressing cells is a well-established technique...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2016
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310923({6-Methylamino-2-[(pyridin-3-ylmethyl)-amino]-thie...)
Affinity DataIC50: 3.5nMAssay Description:Antagonist activity at human adenosine A2B receptor expressed in CHOK1 cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2010
Entry Details Article
PubMed
TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310925({6-dimethylamino-2-[(pyridine-3-ylmethyl)-amino]-t...)
Affinity DataIC50: 6.5nMAssay Description:The use of a Fluorometric Imaging Plate Reader (FLIPR) to measure calcium flux in Adenosine-receptor expressing cells is a well-established technique...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2016
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310924({6-Ethylamino-2-[(pyridin-3-ylmethyl)-amino]-thien...)
Affinity DataIC50: 6.70nMAssay Description:The use of a Fluorometric Imaging Plate Reader (FLIPR) to measure calcium flux in Adenosine-receptor expressing cells is a well-established technique...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2016
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310922({6-Amino-2-[(pyridin-3-ylmethyl)-amino]-thieno[3,2...)
Affinity DataIC50: 7.10nMAssay Description:The use of a Fluorometric Imaging Plate Reader (FLIPR) to measure calcium flux in Adenosine-receptor expressing cells is a well-established technique...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2016
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563259(US11407740, Compound 130)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563298(US11407740, Compound 299)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563268(US11407740, Compound 171)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563275(US11407740, Compound 193)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563144(US11407740, Compound 17)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563267(US11407740, Compound 169)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563154(US11407740, Compound 38)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563146(US11407740, Compound 19 | US11407740, Compound 20)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563255(US11407740, Compound 65)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563273(US11407740, Compound 191)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563294(US11407740, Compound 289)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563263(US11407740, Compound 141)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563289(US11407740, Compound 240 | US11407740, Compound 24...)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563269(US11407740, Compound 172)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563262(US11407740, Compound 139)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563124(US11407740, Compound 7)
Affinity DataIC50: 10nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310932((+/-)-[2-(1-Pyridin-3-yl-ethylamino)-thieno[3,2-d]...)
Affinity DataIC50: 13nMAssay Description:Antagonist activity at human adenosine A2B receptor expressed in CHOK1 cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2010
Entry Details Article
PubMed
TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310921({6-Chloro-2-[(pyridin-3-ylmethyl)-amino]-thieno[3,...)
Affinity DataIC50: 16nMAssay Description:Antagonist activity at human adenosine A2B receptor expressed in CHOK1 cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2010
Entry Details Article
PubMed
TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310909((5-methylthiophen-2-yl)(2-(1-(pyridin-3-yl)ethylam...)
Affinity DataIC50: 17nMAssay Description:Antagonist activity at human adenosine A2B receptor expressed in CHOK1 cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2010
Entry Details Article
PubMed
TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310912((2-(pyridin-3-ylmethylamino)thieno[3,2-d]pyrimidin...)
Affinity DataIC50: 18nMAssay Description:Antagonist activity at human adenosine A2B receptor expressed in CHOK1 cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2010
Entry Details Article
PubMed
TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310934((S)-[2-(1-Pyridin-3-yl-ethylamino)-thieno[3,2-d]py...)
Affinity DataIC50: 18nMAssay Description:Antagonist activity at human adenosine A2B receptor expressed in CHOK1 cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2010
Entry Details Article
PubMed
TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310924({6-Ethylamino-2-[(pyridin-3-ylmethyl)-amino]-thien...)
Affinity DataIC50: 19nMAssay Description:Antagonist activity at human adenosine A2B receptor expressed in CHOK1 cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2010
Entry Details Article
PubMed
TargetAdenosine receptor A2b(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310908((5-methylthiophen-2-yl)(2-(1-(pyridin-2-yl)ethylam...)
Affinity DataIC50: 19nMAssay Description:Antagonist activity at human adenosine A2B receptor expressed in CHOK1 cells assessed as inhibition of calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/17/2010
Entry Details Article
PubMed
TargetAdenosine receptor A1(Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310925({6-dimethylamino-2-[(pyridine-3-ylmethyl)-amino]-t...)
Affinity DataIC50: 19.4nMAssay Description:The use of a Fluorometric Imaging Plate Reader (FLIPR) to measure calcium flux in Adenosine-receptor expressing cells is a well-established technique...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2016
Entry Details
Go to US Patent

TargetAdenosine receptor A3 [I248L](Human)
Vernalis (R&D)

US Patent
LigandPNGBDBM50310923({6-Methylamino-2-[(pyridin-3-ylmethyl)-amino]-thie...)
Affinity DataIC50: 22.9nMAssay Description:The use of a Fluorometric Imaging Plate Reader (FLIPR) to measure calcium flux in Adenosine-receptor expressing cells is a well-established technique...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/25/2016
Entry Details
Go to US Patent

TargetDNA gyrase subunit B(Staphylococcus aureus)
University of Leeds

Curated by ChEMBL
LigandPNGBDBM50058509(CHEMBL3329317)
Affinity DataIC50: 24nMAssay Description:Inhibition of Staphylococcus aureus GyrB assessed reduction in DNA supercoiling activity by malachite green dye based by spectrophotometryMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/1/2016
Entry Details Article
PubMed
TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563258(US11407740, Compound 101)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563265(US11407740, Compound 148)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563280(US11407740, Compound 202)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563272(US11407740, Compound 177)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563174(US11407740, Compound 56)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563175(US11407740, Compound 57)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563293(US11407740, Compound 288)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563257(US11407740, Compound 71)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563274(US11407740, Compound 192)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563254(US11407740, Compound 64)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563180(US11407740, Compound 60)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563156(US11407740, Compound 44)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563279(US11407740, Compound 201)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563295(US11407740, Compound 296)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563296(US11407740, Compound 297)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563289(US11407740, Compound 240 | US11407740, Compound 24...)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563289(US11407740, Compound 240 | US11407740, Compound 24...)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563277(US11407740, Compound 199)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetUDP-3-O-acyl-N-acetylglucosamine deacetylase(Escherichia coli (strain K12))
Forge Therapeutics

US Patent
LigandPNGBDBM563261(US11407740, Compound 138)
Affinity DataIC50: 30nMAssay Description:IC50 values against E. coli LpxC were determined using a Rapid Fire MS assay as previously described J. Med. Chem. 2012, 55, 1662-1670.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 597 total ) | Next | Last >>
Jump to: